Canada markets closed

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
7.510.00 (0.00%)
At close: 11:40AM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • J
    Juerg
    Is there anybody outthere with an opinion on RX. Best regards and stay safe & healthy!
  • S
    S
    Such a good stock. With great risk reward balance. Only thing is the very low volume.
  • T
    The
    Management is averse to promoting its own share price. It does not give future guidance and won't say anything positive about the share although it may be considering. The CEO, Rene Goehrum in his presentation on the 3rd quarter vaguely said "If we have capital that we believe is in excess of our strategy, we will turn that to shareholders. The obvious way to do that is dividends and share buybacks..". Given that the share buybacks have reduced to a trickle and that the float is not large, the 'obvious' way is now dividends. Expect a maiden dividend next year.
  • S
    Steven
    I was going to point out in the post below that BIYOF has 23% of its market value in cash and they are very profitable now, plus they are growing, and they are buying back their shares! The CEO owns 10% of the outstanding shares so he has skin in the game.
  • T
    The
    BioSyent Inc. is on a trajectory to grow double digit over the next few years. It is very conservative with capital deployment but suspect with the $27 million in cash it is going to be forced to deploy the capital a little more aggressively that it traditionally has. If that happens it will grow with enormous gross margins of 78%+ and that is most likely to drop down to the bottom line. It is also spending a lot on promoting its 2 new products Tibolone and Combogesic, a combination of two very popular OTC medications into one. Though it has begun to advertise aggressively, its ability to tell doctors about these meds is better than spending millions on advertising.
  • F
    Four-buck- Chuck
    looking forward to next earnings. Steady growth over the last couple years. Since nobody seems to promote this stock, I suspect when that happens holders will be happy.
  • C
    C
    Great company. No traffic at all.
  • B
    Brad
    what is the point of companies like this to go public? Small no volume
  • F
    Fernando
    interview with forecasts for the company: https://www.youtube.com/watch?v=BTQ7p4MbJtM. more than double revenue!
  • S
    Steven
    I had a long post about this stock and where I found out about it. But now it is gone. Why was it pulled?
  • D
    Daniel
    Doesn't move at all in a day lol
  • a
    ada
    I am in!